BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aegis Therapeutics, LLC Awarded Patent for Interferon Alpha, Beta, and Gamma Formulations That Eliminate Aggregation and Associated Immunogenicity and Are Suitable for Non-Invasive or Injectable Delivery


1/4/2012 8:43:11 AM

SAN DIEGO, CA--(Marketwire - January 04, 2012) -

Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,084,022 providing broad protection for stabilized formulations of alpha, beta, and gamma interferon suitable for non-invasive metered nasal spray delivery or traditional injection. Examples of approved interferon drugs include Betaferon®/Betaseron®/ (Bayer), Avonex®/ (Biogen Idec), Rebif®/ (EMD Serono/Pfizer), Laroféron (Roche), Roferon-A (Roche), Canferon® (Takeda) and Actimmune® (Genentech). The beta interferons are indicated for the treatment of multiple sclerosis and the alpha interferons are used for treatment of chronic hepatitis C and hairy cell leukemia. Gamma interferon is used in the treatment of chronic granulomatous disease and severe malignant osteopetrosis.

Aegis will begin seeking potential licensees for this most recently issued patent for its ProTek® protein stabilization and immunogenicity reduction technology. Other issued ProTek® related patents provide for non-invasive delivery and stabilization of GLP-1 analogs, human growth hormone, and PTH, with others pending.

About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in most protein injectable drugs.

For more information about Aegis, please visit: http://www.aegisthera.com.


Contact:
Ralph Barry
Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES